Federica Belmonte

Federica Belmonte

Auto-generated profile, based on publicly available information

Federica Belmonte

Statistics and Data Analysis, Danish Cancer Institute, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SKSusanne K. Kjaer
Susanne K. Kjaer
CDChristian Dehlendorff
Christian Dehlendorff
FBFederica Belmonte
Federica Belmonte
LBLouise Baandrup
Louise Baandrup
Background: The primary goal of human papillomavirus (HPV) vaccination is to reduce morbidity and mortality from HPV-associated disease, especially cervical cancer. We determined the real-world effectiveness of HPV vaccination against cervical cancer. Methods: The study included women aged 17-30 years living in Denmark October 2006-December 2019. From nationwide registries, information on HPV vaccination and cervical cancer diagnoses were retrieved. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for cervical cancer according to vaccination status were estimated using Poisson regression with HPV vaccination treated as a time-varying variable and stratified by age at vaccination. We adjusted for attained age, education, and ethnicity. To address the effect of prevalent disease, different buffer periods were used, with 1-year buffer period as primary analysis. Results: The cohort comprised 867 689 women. At baseline, 36.3% were vaccinated at age 16 years and younger, and during follow-up, 19.3% and 2.3% were vaccinated at ages 17-19 years and 20-30 years, respectively. For women vaccinated at ages 16 years and younger or 17-19 years, the IRRs of cervical cancer were 0.14 (95% CI = 0.04 to 0.53) and 0.32 (95% CI = 0.08 to 1.28), respectively, compared with unvaccinated women. In women aged 20-30 years at vaccination, the incidence rate was higher than among unvaccinated women (IRR = 1.19, 95% CI = 0.80 to 1.79) but slightly decreased with increasing buffer period (IRR = 0.85, 95% CI = 0.55 to 1.32, with 4-year buffer period). Conclusion: HPV vaccine effectiveness against cervical cancer at the population level is high among girls vaccinated younger than age 20 years. The lack of immediate effect in women vaccinated at age 20-30 years points to the importance of early age at vaccination.

6 March 2020 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
CCCecilie D. de la Cour
Cecilie D. de la Cour
CSCecilie D. Sperling
Cecilie D. Sperling
FBFederica Belmonte
Federica Belmonte
SSStina Syrjänen
Stina Syrjänen
SKSusanne K. Kjaer
Susanne K. Kjaer

1 April 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
AUAivara Urbute
Aivara Urbute
CRChristina Louise Rasmussen
Christina Louise Rasmussen
FBFederica Belmonte
Federica Belmonte
TOTheresa Obermueller
Theresa Obermueller
EPElena-Sophie Prigge
Elena-Sophie Prigge
SKSusanne K. Kjaer
Susanne K. Kjaer
We conducted a systematic review and meta-analysis of observational studies evaluating survival in patients with anal cancer, according to human papillomavirus (HPV) DNA, p16INK4a, and combined HPV DNA/p16INK4a status. We systematically searched PubMed, EMBASE, and Cochrane Library databases to identify studies published in English until July 25, 2018, directly providing or allowing estimation of survival of patients with anal cancer according to the presence of HPV DNA and/or overexpression of p16INK4a. We estimated pooled HRs and 95% confidence intervals (CI) for overall survival (OS) using a random-effects model. We included 16 studies, comprising 1,724 patients with anal cancer tested for HPV DNA (65% positive), and 567 patients tested for p16INK4a (87% positive). The pooled HR for OS was 0.54 (95% CI, 0.33–0.89) for HPV DNA positive versus negative, 0.37 (95% CI, 0.24–0.57) for p16INK4a positive versus negative, and 0.36 (95% CI, 0.22–0.58) for HPV DNA positive/p16INK4a positive versus HPV DNA positive/p16INK4a negative patients with anal cancer. Patients with HPV DNA or p16INK4a positive anal cancer have significantly better OS compared with HPV DNA or p16INK4a negative. This points to the possible value of HPV DNA and/or p16INK4a testing when planning the management and follow-up strategy for patients diagnosed with anal cancer.

27 December 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
HSHanin Salem
Hanin Salem
AKAnne E. Kazak
Anne E. Kazak
EAElisabeth Wreford Andersen
Elisabeth Wreford Andersen
FBFederica Belmonte
Federica Belmonte
CJChristoffer Johansen
Christoffer Johansen
PBPernille E. Bidstrup
Pernille E. Bidstrup

10 June 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LSLena Saltbæk
Lena Saltbæk
PBPernille E. Bidstrup
Pernille E. Bidstrup
RKRandi V. Karlsen
Randi V. Karlsen
BHBeverley Lim Hoeg
Beverley Lim Hoeg
THTrine A. Horsboel
Trine A. Horsboel
CJChristoffer Johansen
Christoffer Johansen
PURPOSE: Follow-up after breast cancer with regular visits has failed to detect recurrences, be cost-effective, and address patient needs. METHODS: MyHealth is a phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT02949167 ). Patients, who recently completed primary treatment for stage I-II breast cancer, were randomly assigned in variable block sizes and stratified by age and human epidermal growth factor receptor 2 status to intervention or control follow-up. The nurse-led intervention comprised three to five individual self-management sessions, regular reporting of symptoms, and navigation to health care services. The control follow-up comprised regular outpatient visits with the physician. The primary outcome was breast cancer–specific quality of life (QoL) measured by the Trial Outcome Index-Physical/Functional/Breast summary score of the Functional Assessment of Cancer Therapy-Breast 2 years after random assignment. Secondary outcomes were fear of recurrence, anxiety, depression, and health care utilization. Analyses were intention-to-treat and P values were two-sided with 95% confidence level set at 0.005 because of multiple comparisons. RESULTS: Among 1,101 eligible patients, 875 were invited and 503 were randomly assigned to control (n = 252) or intervention (n = 251) follow-up. At 2 years, patients in the intervention group reported a significantly and clinically relevant higher QoL (mean, 75.69 [standard deviation [SD], 12.27]) than patients in the control group (71.26 [SD, 14.08]), with a mean difference of 5.05 (95% CI, 3.30 to 6.79; P < .001). The intervention group reported significantly less fear of recurrence, anxiety, and depression; they had fewer physician consultations but more nurse contacts and an unchanged diagnostic imaging pattern. The effect on all outcomes was stable through a 3-year follow-up. CONCLUSION: The MyHealth study suggested a new strategy for follow-up after early breast cancer as it provided significant improvements in QoL.

23 June 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
CCCecilie Dovey de la Cour
Cecilie Dovey de la Cour
CSCecilie Dyg Sperling
Cecilie Dyg Sperling
FBFederica Belmonte
Federica Belmonte
SSstina syrjänen
stina syrjänen
FVFreija Verdoodt
Freija Verdoodt
SKSusanne K. Kjaer
Susanne K. Kjaer